EPO Art. 54(2) • Novelty Loop
CRISPR-Cas9 EPO Art. 54(2) Novelty Loop
EP 2 305 838 B1 • Art. 54(2) EPC Novelty
72/100 — Novelty Gap
Art. 54(2) EPC Einwand: sgRNA-Struktur durch Jinek 2012 vollständig anticipiert
1
Ausgangslage
Technisches Umfeld und Art der Ablehnung.
| Patent | EP 2 305 838 B1 — CRISPR-Cas9 System für Genom-Editierung in Eukaryontischen Zellen |
| Tech Field | Biotechnology — CRISPR-Cas9 Gene Editing |
| OA Type | EPO Examination Communication — Art. 54(2) EPC Novelty objection |
| Rejection | Claim 1 lacks novelty; Examining Division cites Jinek 2012 (Science 337:816) as fully anticipating the sgRNA genus and functional RNP complex; eukaryotic wording deemed generic and not structurally limiting. |
| Key Issue | Guide-RNA sequence identity + sgRNA structural anticipation by Jinek 2012; specificity of ≥20 nt spacer length and RNP delivery modality not disclosed in Jinek; restriction to human (mammalian) cells. |
Agent: OA empfangen → Art. 54(2) EPC Neuheitseinwand identifiziert → Gap-Analyse (sgRNA-Spacer-Länge + RNP-Delivery vs. Jinek 2012 prokaryotische Lehre) gestartet.
2
Original-Claims
Die beanspruchten Ansprüche 1-3, wie ursprünglich eingereicht.
| Typ | Nr. | Inhalt |
|---|---|---|
| Unabhängig | 1 | Use of a CRISPR-Cas9 system comprising a guide RNA (gRNA) and a Cas9 endonuclease for editing a target DNA sequence in a eukaryotic cell, wherein the gRNA directs the Cas9 endonuclease to the target DNA sequence via Watson-Crick base pairing. |
| Unabhängig | 2 | A method for editing a target DNA sequence in a eukaryotic cell, comprising: providing a gRNA comprising a spacer sequence of 15–25 nucleotides; providing a Cas9 endonuclease; forming a ribonucleoprotein (RNP) complex; introducing the RNP complex into the eukaryotic cell; cleaving the target DNA sequence. |
| Unabhängig | 3 | A kit comprising: a gRNA and a Cas9 endonuclease for use in a method according to claim 2. |
3
OA-Parsing-Output
ClaimForge's OA-Agent hat die Examination Communication strukturiert extrahiert.
Art. 54(2) EPC — Novelty Objection
Rejection Summary
Art. 54(2) EPC — claim 1 lacks novelty over D1 (Jinek 2012, Science 337:816)
Primary Ref D1
- D1 Quelle: Jinek et al. (2012), "A programmable dual-RNA–guided DNA endonuclease in adaptive bacterial immunity", Science 337(6096):816-21
- Passage: D1 discloses single-guide RNA (sgRNA) + Cas9 for DNA cleavage in prokaryotic systems; teaches the RNP complex formation principle and sgRNA structural scaffold. Examiner argues the sgRNA genus and Cas9 RNP mechanism are fully disclosed, making the claim scope anticipated.
- Note: D1 does not disclose spacer length ≥20 nt as a specific requirement, RNP delivery into human cells, or restriction to mammalian cell lines.
Secondary Ref D2
- D2 Quelle: Doudna & Charpentier (2012), PCT/US2013/032589 priority; Science 346:1258096 (2014)
- Passage: D2 describes the foundational sgRNA + Cas9 system in prokaryotes. Does not address eukaryotic delivery, spacer-length specificity, or RNP formulation for mammalian use.
Examiner's Argument: Jinek 2012 discloses the complete sgRNA + Cas9 RNP mechanism; the eukaryotic scope in claim 1 is not a structural limitation and the skilled person would immediately apply the disclosed system to eukaryotic cells. The sgRNA genus is fully anticipated.
PSA Technical Problem: How to provide a CRISPR-Cas9 system with sufficient novelty over Jinek 2012 for genome editing specifically in human cells with defined spacer-length parameters?
Novelty Gap Score
72
/ 100
Agent: OA analysiert → Art. 54(2) Neuheitslücke: Jinek 2012 prokaryotische Lehre vs. sgRNA-Spacer-Länge ≥20 nt + RNP-Delivery in Humanzellen → Amendment-Vorschlag generiert.
4
Claim-Amendments (rot markiert)
Rot markierte Änderungsvorschläge für Anspruch 1 mit Spec-Ankern.
Amended Claim 1 (Neu)
Use of a CRISPR-Cas9 system comprising a guide RNA (gRNA) and a Cas9 endonuclease for editing a target DNA sequence in a human cell, characterized in that: (a) the gRNA comprises a spacer sequence of at least 20 nucleotides that is complementary to the target DNA sequence, (b) the Cas9 endonuclease is delivered as a ribonucleoprotein (RNP) complex with the gRNA, and (c) the RNP complex is introduced into the human cell by electroporation or lipid nanoparticle (LNP) delivery, wherein the target DNA sequence is located in the nuclear genome of the human cell.
Spec-Anker:
[0031] (spacer sequence ≥20 nt)
[0042] (RNP complex formation + delivery)
[0055] (electroporation + LNP delivery modality)
[0067] (restriction to human nuclear genome)
Key Additions vs. Original
| Element | Zusammenfassung |
|---|---|
| 01 | Spacer length ≥20 nt — structural specificity not disclosed in Jinek 2012 prokaryotic sgRNA scaffold |
| 02 | RNP delivery (not plasmid or in vitro transcription) — delivery modality as structural claim element |
| 03 | Restriction to human cell line — narrows genus to mammalian nuclear editing, not anticipated by prokaryotic D1 |
Agent: Anspruch 1 geändert → 3 strukturelle Unterscheidungsmerkmale (Spacer-Länge ≥20 nt, RNP-Delivery, Humanzellen) → Counter-Arguments werden generiert.
5
Counter-Arguments-Draft (EPO-Format)
Vollständiger Entwurf der Erwiderung auf die Examination Communication.
RESPONSE TO EXAMINER'S COMMUNICATION
European Patent Application No. [App#]
Novelty Objection — Art. 54(2) EPC
The Examining Division objects that claim 1 lacks novelty under Art. 54(2) EPC over D1 (Jinek 2012). Applicant submits the following response.
I. NOVELTY REQUIREMENT UNDER ART. 54(2) EPC
Art. 54(2) EPC provides that an invention shall be considered new if it does not form part of the state of the art. The state of the art comprises everything made available to the public before the filing date of the European patent application. Anticipation requires a single prior-art document to disclose each and every feature of the claimed subject-matter. D1 does not meet this standard for the following reasons.
II. DISTINGUISHING FEATURES NOT DISCLOSED IN D1
(a) Spacer length ≥20 nucleotides (feature (a))
D1 discloses sgRNA guides of varying lengths in prokaryotic systems but does not specify or require a spacer length of at least 20 nucleotides as a structural claim element. The ≥20 nt requirement is not implicit from D1's prokaryotic context and is a structural feature supported by paragraph [0031] of the present application. A novelty challenge requires disclosure of this feature in a single document — D1 does not provide it.
(b) RNP delivery modality (feature (b))
D1 discloses in vitro cleavage assays using purified Cas9 + sgRNA but does not disclose delivering the Cas9 as a pre-formed RNP complex into a living cell. The RNP delivery modality as a structural element of the claimed use is absent from D1. This is supported by paragraph [0042] of the specification.
(c) Restriction to human cells (scope limitation)
Claim 1 as amended is explicitly restricted to "human cell" rather than the broader "eukaryotic cell." D1 operates exclusively in prokaryotic (bacterial) cell-free systems. Extension to human cells requires nuclear localization, chromatin accessibility considerations, and codon-optimized expression — none of which are disclosed in D1.
III. COMBINATION OF D1 + D2 IS IRRELEVANT FOR NOVELTY
Novelty under Art. 54(2) EPC is assessed against a single prior-art document. D1 + D2 together cannot anticipate claim 1; that analysis belongs under Art. 56 EPC (inventive step). The examiner's argument concerning the skilled person's general knowledge is therefore not a valid novelty objection.
IV. CONCLUSION
The subject-matter of amended claim 1 is novel under Art. 54(2) EPC over D1 (Jinek 2012) and D2.
Allowance of the amended claims is respectfully requested.
Agent: Counter-Arguments generiert (8 Min.) → Autonomous Re-Search auf amended Claims gestartet.
6
Autonomous Re-Search (Amended Claims)
Re-Search nach automatischer Änderung der Ansprüche — Espacenet + Google Patents.
| Rank | Patent / Dokument | Score | Unterscheidung |
|---|---|---|---|
| 1 | WO 2013/176772 Cong et al. 2013 |
68/100 | sgRNA + Cas9 in human cells — no ≥20 nt spacer length requirement; no RNP delivery specification |
| 2 | WO 2013/142578 Mali et al. 2013 |
61/100 | sgRNA + Cas9 in HEK293 cells — no RNP delivery; no spacer-length ≥20 nt limitation |
| 3 | EP 2 784 162 B1 MilliporeSigma |
54/100 | CRISPR gene editing in eukaryotes — no specific spacer length requirement or RNP delivery modality |
| 4 | Jinek et al. 2012 (NPL) Science 337:816 |
71/100 | Prokaryotic RNP but no human cells; primary examiner reference — partially overlaps sgRNA scaffold but not ≥20 nt specificity |
| 5 | Doudna & Charpentier 2014 (NPL) Science 346:1258096 |
49/100 | Foundational but prokaryotic; no ≥20 nt spacer specificity; no human cell restriction |
Re-Search Verdict
No prior art combines ≥20 nt spacer length + RNP delivery + human nuclear genome restriction. Highest Art. 54 threat (Jinek 2012) falls to 71/100 post-amendment — specific spacer-length and RNP delivery features remain undisclosed. Confidence: 78%.
Confidence: 78%
Agent: Re-Search abgeschlossen. Fünf Prior-Art-Pathways analysiert. Kein Dokument kombiniert ≥20 nt Spacer-Länge + RNP-Delivery + Humanzellen → Chain abgeschlossen.
Demo
Agent-Output: Screenshots
Vier Demo-Screenshots des autonomen Loops.
7
Verdict
Ergebnis der automatischen Chain-Analyse.
Action:
Pass (conditional)
Strong novelty differentiation via ≥20 nt spacer length + RNP delivery + human-cell restriction.
No single prior-art document discloses all three amended features. Art. 54(2) challenge from Jinek 2012 addressed. Confidence: 78%.
Human check required: spec support for amended elements ([0031], [0042], [0055], [0067]); Art. 54(3) earlier-filed EP applications not searched; Broad vs. CVC priority date chain must be verified by human counsel before filing.
8
Was der Loop Gespart Hat
Zeitvergleich: manuell vs. ClaimForge Loop.
| Szenario | Stunden |
|---|---|
| Ohne ClaimForge | 20–28 h |
| ClaimForge Loop | 2.5 h |
| Netto-Ersparnis | 18–24 h |
Caveat: EPO oral proceedings not covered; Art. 123(2) added-matter check required by human attorney before filing; Broad vs. CVC priority chain not adjudicated by this loop.
9
Limits
Was ClaimForge in diesem Loop nicht abdeckt.
- Art. 54(3) EPC: earlier-filed EP applications not yet published at priority date are not covered by this loop's search
- Broad vs. CVC priority chain: not adjudicated by ClaimForge — human counsel must verify priority date authenticity
- EPO oral proceedings: human attorney required if examining division maintains Art. 54 objection after written response
- Art. 123(2) added matter: automated check flags potential issues; human verification of spec anchors [0031], [0042], [0055], [0067] required
10
Probieren Sie den Loop
CRISPR / Biotech als Demo-Szenario
ClaimForge's autonomer Loop kann über den gesamten Prosecution-Workflow eingesetzt werden — von der Prior-Art-Recherche über Claim-Tree-Generierung bis zur Office-Action-Erwiderung, auch für Biotech-Patente mit komplexen molekularbiologischen Unterscheidungsmerkmalen.